Skip to main content

Table 6 Multivariate logistic regression analysis of infliximab/vedolizumab use and hospital admission

From: Importance of endoscopic and histological evaluation in the management of immune checkpoint inhibitor-induced colitis

Characteristic

Infliximab/vedolizumab use

Hospital admission

OR (95% CI)

P value

OR (95% CI)

P value

Age

0.98 (0.95–1.01)

0.20

1.00 (0.98–1.02)

0.93

CTLA-4 based therapy

1.92 (0.68–5.37)

0.22

1.26 (0.58–2.74)

0.55

Duration of ICPI treatment

1.00 (0.99–1.01)

0.17

1.00 (1.00–1.01)

< 0.01

High-risk endoscopic features

3.93 (1.69–9.12)

< 0.01

1.74 (0.79–3.87)

0.17

Active histological inflammation

2.32 (0.60–8.99)

0.22

1.39 (0.64–3.02)

0.40

  1. Abbreviation: ICPI immune checkpoint inhibitor, CTLA-4 cytotoxic T-lymphocyte antigen-4, OR odds ratio, CI confidence interval
Back to article page